Patterns Of Care

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)Case: A man in his early 70s with mantle c

Featuring a slide presentation from Dr Julia Rotow, including the following topics:Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00)CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00)CME information and select publications

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:Introduction (0:00)New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)Managing brain metastases in triple-negative breast cancer (6:30)EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:Introduction (0:00)Minimal Residual Disease Assays in Community-Based Practice (1:24)New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)Richter Transformation (30:43)Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00)Case: A woman in her mid 50s with ovarian cancer and a genomic instability score of 50, folate receptor alpha 90%, HER2 IHC 2+, and BRCA1/2 wild-type disease treated initially with surgery, carboplatin/paclitaxel and maintenance olaparib/bevacizumab — Dr Ursula Matulonis (8:46)CME information and select publications

Featuring an interview with Dr L Elizabeth Budde, including the following topics:Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)CME information and select publications

Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)EGFR Mutations (2:23)HER2 Alterations (22:40)Available and Investigational Immunotherapies (32:14)Small Cell Lung Cancer (40:48)CME information and select publications

Featuring an interview with Dr Neeraj Agarwal, including the following topics:Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)Managing treatment-related adverse events from capivasertib (20:08)Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00)Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29)CME information and select publications

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)CME information and select publications

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)Ovarian Cancer (2:22)Endometrial Cancer (37:48)CME information and select publications

Featuring an interview with Dr Alexander E Drilon, including the following topics:Overview of targetable biomarkers in lung cancer (0:00)Biomarker testing for genomic alterations in lung cancer (5:24)Overview of ROS1 alterations in lung cancer (13:44)Efficacy data with ROS1 inhibitors for lung cancer (17:02)Safety data with ROS1 inhibitors for lung cancer (21:15)Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)NCPD information and select publications

Featuring an interview with Professor Nicoletta Colombo, including the following topics:Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00)Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31)Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02)Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25)Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43)Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46)CME information and select publications

Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)Management of HER2-Positive Gastroesophageal Cancer (25:11)Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.CME information and select publications